Tyypin 1 diabetes

The Type 1 Diabetes (T1D) field is evolving.

Recognition of the presymptomatic stages in T1D is growing.^1-4 

The clinical benefits of early detection of T1D are being highlighted.^3-4 Programmes focusing on early detection through testing and screening for presymptomatic autoimmune T1D are increasingly offered to risk populations and the general population.^1,2

Autoimmune Type 1 diabetes (T1D) is undergoing a fundamental transformation in how the medical community approaches diagnosis and care.

Autoimmune Type 1 Diabetes (T1D) can be detected through islet autoantibody testing years before symptoms appear.^1-2 The video here explains how the condition progresses silently through presymptomatic stages, with beta cell destruction occurring long before symptom onset and clinical diagnosis.^4-8

Parent's experiences of stage 3 diagnosis of T1D.

The progression of autoimmune type 1 diabetes (T1D) is gradual, often detectable months or even years before symptoms arise.^1–3 Through proactive screening, we can identify the condition well in advance.³ Meet our ambassadors living with autoimmune T1D and discover the risk factors to look out for when considering who to screen.

Delay in screening for autoimmune type 1 diabetes (T1D) can increase the risk of diabetic ketoacidosis (DKA) at diagnosis—a critical complication that is potentially life-threatening and may result in long-term poor glycemic control and neurological complications.^1,2 By identifying autoimmune T1D early, you can significantly lower the risk of DKA at diagnosis.^3,4

Autoimmune type 1 diabetes (T1D) is a progressive disease in which the decline in beta cell function usually begins months or sometimes years before clinical symptoms are observed.^1–3 You can identify such patients at risk of developing autoimmune T1D before clinical symptoms are noticed by you or your patient.³